Orexins/Hypocretins: Pain regulation and cellular actions

Current Pharmaceutical Design

Volumn 16, Issue 28, 2010, Pages 3089-3100

  Chiou, Lih Chu ^a,b,c   Lee, Hsin Jung ^a   Ho, Yu Cheng ^a   Chen, Shih Pin ^d,e   Liao, Yan Yu ^a   Ma, Chia Hau ^c   Fan, Pi Chuan ^a,b,c   Fuh, Jong Ling ^d,e   Wang, Shuu Jiun ^d,e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cluster headache; Endocannabinoids; Migraine; Nociceptin Orphanin FQ; Orexins Hypocretins; OX1 OX2 receptors; Pain

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (6,8 DIFLUORO 2 METHYL 4 QUINOLINYL) 3 (4 DIMETHYLAMINOPHENYL)UREA; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 AMINOBUTYRIC ACID; ACT 078573; ALMOREXANT; DORA 1; EMPA; ENDOCANNABINOID; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; GLUTAMIC ACID; GLYCINE RECEPTOR; JNJ 10397049; MESSENGER RNA; NOCICEPTIN; OPIATE; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B; PHOSPHOLIPASE C INHIBITOR; PURINERGIC P2X RECEPTOR; RECEPTOR BLOCKING AGENT; SB 649868; SB 674042; SODIUM CALCIUM EXCHANGE PROTEIN; SOMATOSTATIN; SURAMIN; TCS OX2 29; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID RELEASE; AGONIST; AMBIGUUS NUCLEUS; ANALGESIA; ANTINOCICEPTION; ARCUATE NUCLEUS; BASAL GANGLION; BRAIN DEPTH STIMULATION; BRAIN SLICE; CELL FUNCTION; CHOLINERGIC NERVE CELL; CHRONIC CLUSTER HEADACHE; CHRONIC DAILY HEADACHE; CLUSTER HEADACHE; DIABETIC NEUROPATHY; DORSAL RAPHE NUCLEUS; DRUG MECHANISM; DRUG SELECTIVITY; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; GABAERGIC TRANSMISSION; HIPPOCAMPUS; HOT PLATE TEST; HUMAN; HYPOTHALAMUS NUCLEUS; IMMUNOHISTOCHEMISTRY; INSOMNIA; LATERAL HYPOTHALAMUS; LOCUS CERULEUS; MIGRAINE; MOLECULAR INTERACTION; MOTONEURON NUCLEUS; MYENTERIC PLEXUS; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PERIAQUEDUCTAL GRAY MATTER; POSTOPERATIVE PAIN; PREOPTIC AREA; PRIMARY HEADACHE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; RETICULAR FORMATION; REVIEW; SPINAL CORD; SPINAL GANGLION; TAIL FLICK TEST; THALAMUS NUCLEUS; THALAMUS VENTRAL NUCLEUS; TRANSFORMED MIGRAINE; TRIGEMINAL NUCLEUS; TRIGEMINOVASCULAR PAIN; VENTRAL TEGMENTUM;

ANALGESICS; ANIMALS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROPEPTIDES; PAIN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE;

EID: 78649899402     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793292483     Document Type: Review

References (125)

1. Stadel JM, Wilson S, Bergsma DJ. Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery. Trends Pharmacol Sci 1997; 18: 430-7.
2. Chiou LC, Liao YY, Fan PC, et al. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Curr Drug Targets 2007; 8: 117-35.
3. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G proteincoupled receptors that regulate feeding behavior. Cell 1998; 92: 573-85.
4. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998; 95: 322-7.
5. Zhu Y, Miwa Y, Yamanaka A, et al. Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and-insensitive G-proteins. J Pharmacol Sci 2003; 92: 259-66.
6. Tang J, Chen J, Ramanjaneya M, Punn A, Conner AC, Randeva HS. The signalling profile of recombinant human orexin-2 receptor. Cell Signal 2008; 20: 1651-61.
7. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. Distribution of orexin neurons in the adult rat brain. Brain Res 1999; 827: 243-60.
8. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18: 9996-10015.
9. Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett 1998; 438: 71-5.
10. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001; 435: 6-25.
11. Hervieu GJ, Cluderay JE, Harrison DC, Roberts JC, Leslie RA. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience 2001; 103: 777-97.
12. Cluderay JE, Harrison DC, Hervieu GJ. Protein distribution of the orexin-2 receptor in the rat central nervous system. Regul Pept 2002; 104: 131-44.
13. Malherbe P, Borroni E, Gobbi L, et al. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br J Pharmacol 2009; 156: 1326-41.
14. Boss C, Brisbare-Roch C, Jenck F. Biomedical application of orexin/hypocretin receptor ligands in neuroscience. J Med Chem 2009; 52: 891-903.
15. Smart D, Sabido-David C, Brough SJ, et al. SB-334867-A: the first selective orexin-1 receptor antagonist. Br J Pharmacol 2001; 132: 1179-82.
16. Hirose M, Egashira S, Goto Y, et al. N-acyl 6,7-dimethoxy-1,2,3,4- tetrahydroisoquinoline: the first orexin-2 receptor selective nonpeptidic antagonist. Bioorg Med Chem Lett 2003; 13: 4497-9.
17. McAtee LC, Sutton SW, Rudolph DA, et al. Novel substituted 4- phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg Med Chem Lett 2004; 14: 4225-9.
18. Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007; 13: 150-5.
19. Roecker AJ, Coleman PJ. Orexin receptor antagonists: medicinal chemistry and therapeutic potential. Curr Top Med Chem 2008; 8: 977-87.
20. Asahi S, Egashira S, Matsuda M, et al. Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B. Bioorg Med Chem Lett 2003; 13: 111-3.
21. Hwang LL, Chen CT, Dun NJ. Mechanisms of orexin-induced depolarizations in rat dorsal motor nucleus of vagus neurones in vitro. J Physiol 2001; 537: 511-20.
22. Liu RJ, van den Pol AN, Aghajanian GK. Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci 2002; 22: 9453-64.
23. Murai Y, Akaike T. Orexins cause depolarization via nonselective cationic and K+ channels in isolated locus coeruleus neurons. Neurosci Res 2005; 51: 55-65.
24. Yang B, Ferguson AV. Orexin-A depolarizes dissociated rat area postrema neurons through activation of a nonselective cationic conductance. J Neurosci 2002; 22: 6303-8.
25. Yang B, Ferguson AV. Orexin-A depolarizes nucleus tractus solitarius neurons through effects on nonselective cationic and K+ conductances. J Neurophysiol 2003; 89: 2167-75.
26. Chiou LC, Ho YC. Orexin A inhibits GABAergic neurotransmission via retrograde endocannabinoid through OX1 receptor activation in the ventrolateral periaqueductal gray - A novel antinociceptive mechanism of orexin A. Chicago, IL., USA. Neuroscience 2009; Prog. No. 418.4.
27. Ishibashi M, Takano S, Yanagida H, et al. Effects of orexins/ hypocretins on neuronal activity in the paraventricular nucleus of the thalamus in rats in vitro. Peptides 2005; 26: 471-81.
28. Ivanov A, Aston-Jones G. Hypocretin/orexin depolarizes and decreases potassium conductance in locus coeruleus neurons. Neuroreport 2000; 11: 1755-8.
29. Katayama Y, Hirai K, Homma T, Noda Y, Honda K. Actions of orexins on individual myenteric neurons of the guinea-pig ileum: orexin A or B? Neuroreport 2005; 16: 745-9.
30. Burdakov D, Liss B, Ashcroft FM. Orexin excites GABAergic neurons of the arcuate nucleus by activating the sodium--calcium exchanger. J Neurosci 2003; 23: 4951-7.
31. Eriksson KS, Sergeeva O, Brown RE, Haas HL. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci 2001; 21: 9273-9.
32. Hoang QV, Bajic D, Yanagisawa M, Nakajima S, Nakajima Y. Effects of orexin (hypocretin) on GIRK channels. J Neurophysiol 2003; 90: 693-702.
33. Sergeeva OA, Korotkova TM, Scherer A, Brown RE, Haas HL. Co-expression of non-selective cation channels of the transient receptor potential canonical family in central aminergic neurones. J Neurochem 2003; 85: 1547-52.
34. Borgland SL, Storm E, Bonci A. Orexin B/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons. Eur J Neurosci 2008; 28: 1545-56.
35. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 2006; 49: 589-601.
36. Haj-Dahmane S, Shen RY. The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling. J Neurosci 2005; 25: 896-905.
37. Samson WK, Taylor MM, Ferguson AV. Non-sleep effects of hypocretin/orexin. Sleep Med Rev 2005; 9: 243-52.
38. Tsujino N, Sakurai T. Orexin/Hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev 2009; 61: 162-76.
39. de Lecea L. A decade of hypocretins: past, present and future of the neurobiology of arousal. Acta Physiol (Oxf) 2009.
40. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355: 39-40.
41. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437-51.
42. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365-76.
43. Fronczek R, Baumann CR, Lammers GJ, Bassetti CL, Overeem S. Hypocretin/orexin disturbances in neurological disorders. Sleep Med Rev 2009; 13: 9-22.
44. Aston-Jones G, Smith RJ, Moorman DE, Richardson KA. Role of lateral hypothalamic orexin neurons in reward processing and addiction. Neuropharmacology 2009; 56 Suppl 1: 112-21.
45. Winrow CJ, Tanis KQ, Reiss DR, et al. Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. Neuropharmacology 2010; 58: 185-94.
46. Eriksson KS, Sergeeva OA, Haas HL, Selbach O. Orexins/ hypocretins and aminergic systems. Acta Physiol (Oxf) 2009: Jun 27. [Epub ahead of print], DOI: 10.1111/j.748-716.2009.02015.x.
47. Cheng JK, Hwang LL, Chou RC, Chiou LC. Analgesic effects of orexins. J Neuropath Pain Sympt Palliat 2005; 1: 47-53.
48. Bingham S, Davey PT, Babbs AJ, et al. Orexin-A, an hypothalamic peptide with analgesic properties. Pain 2001; 92: 81-90.
49. Cheng JK, Chou RC, Hwang LL, Chiou LC. Antiallodynic effects of intrathecal orexins in a rat model of postoperative pain. J Pharmacol Exp Ther 2003; 307: 1065-71.
50. Yamamoto T, Nozaki-Taguchi N, Chiba T. Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test. Br J Pharmacol 2002; 137: 170-6.
51. Yamamoto T, Saito O, Shono K, Aoe T, Chiba T. Anti-mechanical allodynic effect of intrathecal and intracerebroventricular injection of orexin-A in the rat neuropathic pain model. Neurosci Lett 2003; 347: 183-6.
52. Yamamoto T, Saito O, Shono K, Hirasawa S. Activation of spinal orexin-1 receptor produces anti-allodynic effect in the rat carrageenan test. Eur J Pharmacol 2003; 481: 175-80.
53. Kajiyama S, Kawamoto M, Shiraishi S, et al. Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecallyadministered orexins in diabetic neuropathic pain model rats. Brain Res 2005; 1044: 76-86.
54. Suyama H, Kawamoto M, Shiraishi S, Gaus S, Kajiyama S, Yuge O. Analgesic effect of intrathecal administration of orexin on neuropathic pain in rats. In Vivo 2004; 18: 119-23.
55. Mobarakeh JI, Takahashi K, Sakurada S, et al. Enhanced antinociception by intracerebroventricularly administered orexin A in histamine H1 or H2 receptor gene knockout mice. Pain 2005; 118: 254-62.
56. Mobarakeh JI, Takahashi K, Sakurada S, et al. Enhanced antinociception by intracerebroventricularly and intrathecally-administered orexin A and B (hypocretin-1 and -2) in mice. Peptides 2005; 26: 767-77.
57. Bartsch T, Levy MJ, Knight YE, Goadsby PJ. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 2004; 109: 367-78.
58. Holland PR, Akerman S, Goadsby PJ. Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther 2005; 315: 1380-5.
59. Holland PR, Akerman S, Goadsby PJ. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci 2006; 24: 2825-33.
60. Lee HJ, Chiou LC. Orexins reduce nociceptive response via endocannabinoid signaling in the midbrain ventrolateral periaqueductal gray. Chicago, IL., USA. Neuroscience 2009, Prog. No. 458.14.
61. Yoshida Y, Fujiki N, Maki RA, Schwarz D, Nishino S. Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats. Neurosci Lett 2003; 346: 182-6.
62. Watanabe S, Kuwaki T, Yanagisawa M, Fukuda Y, Shimoyama M. Persistent pain and stress activate pain-inhibitory orexin pathways. Neuroreport 2005; 16: 5-8.
63. Xie X, Wisor JP, Hara J, et al. Hypocretin/orexin and nociceptin/ orphanin FQ coordinately regulate analgesia in a mouse model of stress-induced analgesia. J Clin Invest 2008; 118: 2471-81.
64. Furlong TM, Vianna DM, Liu L, Carrive P. Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. Eur J Neurosci 2009; 30: 1603-14.
65. Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. N Engl J Med 2002; 346: 257-70.
66. Goadsby PJ. Neurovascular headache and a midbrain vascular malformation: evidence for a role of the brainstem in chronic migraine. Cephalalgia 2002; 22: 107-11.
67. Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet Neurol 2002; 1: 251-7.
68. Kudrow L. The cyclic relationship of natural illumination to cluster period frequency. Cephalalgia 1987; 7 Suppl 6: 76-8.
69. Leone M, Lucini V, D'Amico D, et al. Twenty-four-hour melatonin and cortisol plasma levels in relation to timing of cluster headache. Cephalalgia 1995; 15: 224-9.
70. Alstadhaug KB. Migraine and the hypothalamus. Cephalalgia 2009; 29: 809-17.
71. Holland P, Goadsby PJ. The hypothalamic orexinergic system: pain and primary headaches. Headache 2007; 47: 951-62.
72. Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits meningeal nociception. Ann Neurol 2004; 56: 371-81.
73. Knight YE, Bartsch T, Kaube H, Goadsby PJ. P/Q-type calciumchannel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 2002; 22: RC213.
74. Bruni O, Russo PM, Violani C, Guidetti V. Sleep and migraine: an actigraphic study. Cephalalgia 2004; 24: 134-9.
75. Dexter JD. The relationship between stage III + IV + REM sleep and arousals with migraine. Headache 1979; 19: 364-9.
76. Pfaffenrath V, Pollmann W, Ruther E, Lund R, Hajak G. Onset of nocturnal attacks of chronic cluster headache in relation to sleep stages. Acta Neurol Scand 1986; 73: 403-7.
77. Dahmen N, Kasten M, Wieczorek S, Gencik M, Epplen JT, Ullrich B. Increased frequency of migraine in narcoleptic patients: a confirmatory study. Cephalalgia 2003; 23: 14-9.
78. Stewart WF, Simon D, Shechter A, Lipton RB. Population variation in migraine prevalence: a meta-analysis. J Clin Epidemiol 1995; 48: 269-80.
79. Bigal ME, Lipton RB, Holland PR, Goadsby PJ. Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007; 68: 1851-61.
80. Peterlin BL, Rapoport AM, Kurth T. Migraine and obesity: Epidemiology, Mechanisms, and Implications. Headache 2009.
81. Leone M, Franzini A, Broggi G, Bussone G. Hypothalamic stimulation for intractable cluster headache: long-term experience. Neurology 2006; 67: 150-2.
82. Leone M, Franzini A, Bussone G. Stereotactic stimulation of posterior hypothalamic gray matter in a patient with intractable cluster headache. N Engl J Med 2001; 345: 1428-9.
83. Rainero I, Gallone S, Valfre W, et al. A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache. Neurology 2004; 63: 1286-8.
84. Pinessi L, Binello E, De Martino P, et al. The 1246G-->A polymorphism of the HCRTR2 gene is not associated with migraine. Cephalalgia 2007; 27: 945-9.
85. Schurks M, Kurth T, Geissler I, Tessmann G, Diener HC, Rosskopf D. Cluster headache is associated with the G1246A polymorphism in the hypocretin receptor 2 gene. Neurology 2006; 66: 1917-9.
86. Baumber L, Sjostrand C, Leone M, et al. A genome-wide scan and HCRTR2 candidate gene analysis in a European cluster headache cohort. Neurology 2006; 66: 1888-93.
87. Rainero I, Rubino E, Valfre W, et al. Association between the G1246A polymorphism of the hypocretin receptor 2 gene and cluster headache: a meta-analysis. J Headache Pain 2007; 8: 152-6.
88. Rainero I, Gallone S, Rubino E, et al. Haplotype analysis confirms the association between the HCRTR2 gene and cluster headache. Headache 2008; 48: 1108-14.
89. Yonekura J, Hamada J, Sakai F. Plasma orexin levels in migraine patients. The 13th Congress of the International Headache Society. Stockholm, Sweden.
90. Sarchielli P, Rainero I, Coppola F, et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia 2008; 28: 714-22.
91. Grudt TJ, van den Pol AN, Perl ER. Hypocretin-2 (orexin-B) modulation of superficial dorsal horn activity in rat. J Physiol 2002; 538: 517-25.
92. Li J, Perl ER. ATP modulation of synaptic transmission in the spinal substantia gelatinosa. J Neurosci 1995; 15: 3357-65.
93. Behbehani MM. Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 1995; 46: 575-605.
94. Date Y, Ueta Y, Yamashita H, et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci USA 1999; 96: 748-53.
95. Baldo BA, Daniel RA, Berridge CW, Kelley AE. Overlapping distributions of orexin/hypocretin- and dopamine-beta-hydroxylase immunoreactive fibers in rat brain regions mediating arousal, motivation, and stress. J Comp Neurol 2003; 464: 220-37.
96. Rodgers RJ, Ishii Y, Halford JC, Blundell JE. Orexins and appetite regulation. Neuropeptides 2002; 36: 303-25.
97. Rose SL, Jurs PC. Computer-assisted studies of structure-activity relationships of N-nitroso compounds using pattern recognition. J Med Chem 1982; 25: 769-76.
98. D'Ambra TE, Estep KG, Bell MR, et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 1992; 35: 124-35.
99. Lin LC, Fu SY, Liao YY, Ho IK, Chiou LC. Effects of orexins in the ventrolateral periaqueductal gray-electrophysiological and immunofluorescent studies. Neuroscience 2008, Prog. 826.13. Washington DC, USA.
100. Crespo I, Gomez de Heras R, Rodriguez de Fonseca F, Navarro M. Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1. Neuropharmacology 2008; 54: 219-25.
101. Lang M, Soll RM, Durrenberger F, Dautzenberg FM, Beck-Sickinger AG. Structure-activity studies of orexin a and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands. J Med Chem 2004; 47: 1153-60.
102. Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ. Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 2004; 141: 340-6.
103. Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Mol Pharmacol 2009; 76: 618-31.
104. Whitman DB, Cox CD, Breslin MJ, et al. Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,ndisubstituted-1,4-diazepane scaffold that promotes sleep in rats. ChemMedChem 2009; 4: 1069-74.
105. Aissaoui H, Koberstein R, Zumbrunn C, et al. N-Glycinesulfonamides as potent dual orexin 1/orexin 2 receptor antagonists. Bioorg Med Chem Lett 2008; 18: 5729-33.
106. Bergman JM, Roecker AJ, Mercer SP, et al. Proline bis-amides as potent dual orexin receptor antagonists. Bioorg Med Chem Lett 2008; 18: 1425-30.
107. van den Pol AN, Gao XB, Obrietan K, Kilduff TS, Belousov AB. Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J Neurosci 1998; 18: 7962-71.
108. Nakamura T, Uramura K, Nambu T, et al. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res 2000; 873: 181-7.
109. Antunes VR, Brailoiu GC, Kwok EH, Scruggs P, Dun NJ. Orexins/ hypocretins excite rat sympathetic preganglionic neurons in vivo and in vitro. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1801-7.
110. Burlet S, Tyler CJ, Leonard CS. Direct and indirect excitation of laterodorsal tegmental neurons by Hypocretin/Orexin peptides: implications for wakefulness and narcolepsy. J Neurosci 2002; 22: 2862-72.
111. Wu M, Zhang Z, Leranth C, Xu C, van den Pol AN, Alreja M. Hypocretin increases impulse flow in the septohippocampal GABAergic pathway: implications for arousal via a mechanism of hippocampal disinhibition. J Neurosci 2002; 22: 7754-65.
112. Korotkova TM, Eriksson KS, Haas HL, Brown RE. Selective excitation of GABAergic neurons in the substantia nigra of the rat by orexin/hypocretin in vitro. Regul Pept 2002; 104: 83-9.
113. Davis SF, Williams KW, Xu W, Glatzer NR, Smith BN. Selective enhancement of synaptic inhibition by hypocretin (orexin) in rat vagal motor neurons: implications for autonomic regulation. J Neurosci 2003; 23: 3844-54.
114. Xu R, Roh SG, Gong C, Hernandez M, Ueta Y, Chen C. Orexin-B augments voltage-gated L-type Ca(2+) current via protein kinase C-mediated signalling pathway in ovine somatotropes. Neuroendocrinology 2003; 77: 141-52.
115. Korotkova TM, Sergeeva OA, Eriksson KS, Haas HL, Brown RE. Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. J Neurosci 2003; 23: 7-11.
116. Sergeeva OA, Amberger BT, Eriksson KS, Scherer A, Haas HL. Co-ordinated expression of 5-HT2C receptors with the NCX1 Na+/Ca2+ exchanger in histaminergic neurones. J Neurochem 2003; 87: 657-64.
117. Wu M, Zaborszky L, Hajszan T, van den Pol AN, Alreja M. Hypocretin/orexin innervation and excitation of identified septohippocampal cholinergic neurons. J Neurosci 2004; 24: 3527-36.
118. Dergacheva O, Wang X, Huang ZG, et al. Hypocretin-1 (orexin-A) facilitates inhibitory and diminishes excitatory synaptic pathways to cardiac vagal neurons in the nucleus ambiguus. J Pharmacol Exp Ther 2005; 314: 1322-7.
119. Yan JA, Ge L, Huang W, Song B, Chen XW, Yu ZP. Orexin affects dorsal root ganglion neurons: a mechanism for regulating the spinal nociceptive processing. Physiol Res 2008; 57: 797-800.
120. Shono K, Yamamoto T. Orexin-2 receptors inhibit primary afferent fiber-evoked responses of ventral roots in the neonatal rat isolated spinal cord. Brain Res 2008; 1218: 97-102.
121. Ozcan M, Ayar A, Serhatlioglu I, Alcin E, Sahin Z, Kelestimur H. Orexins activates protein kinase C-mediated Ca(2+) signaling in isolated rat primary sensory neurons. Physiol Res 2009.
122. Huang SC, Dai YW, Li YH, Hwang LL. Orexin A and orexin B depolarize C1 and non-C1 neurons in rostral ventrolateral medulla mainly via OX2R. The 12th SCBA (Society of Chinese Bioscientists in America) International Symposium. Taipei, Taiwan.
123. DeHaven-Hudkins DL, Dolle RE. Peripherally restricted opioid agonists as novel analgesic agents. Curr Pharm Des 2004; 10(7): 743-57.
124. Przewlocki R, Przewlocka B. Opioids in neuropathic pain. Curr Pharm Des 2005; 11(23): 3013-25.
125. Szlachcic A, Brzozowski T, Majka J, Pajdo R, Konturek PC, Pawlik M, Kwiecien S, Drozdowicz D, Bielanski W, Konturek SJ, Pawlik WW. Involvement of orexigenic peptides in the mechanism of gastric mucosal integrity and healing of chronic gastric ulcers. Curr Pharm Des 2010; 16(10): 1214-23.